Amgen Inc. has entered into a three-year research partnership with Cedars-Sinai Medical Center in Los Angeles to assess health outcomes in patients with cancer, osteoporosis, cardiovascular disease and migraine. The Thousand Oaks-based pharmaceutical company announced Thursday that the bulk of its work with the hospital will focus initially on cancer treatments. Though some of the research could include patients who are receiving Amgen products, it will not be exclusive to such individuals, according to the company. Instead, studies will focus on patient experiences more broadly, such as an assessment of how technology can be used to promote medication adherence. “This agreement with Cedars-Sinai will seek to gather data about available treatment options to help improve clinical outcomes and patient experience in therapeutic areas with significant unmet need,” Dr. Peter Juhn, vice president of global value-based partnerships at Amgen, said in a statement. Shares of Amgen (AMGN) fell Thursday $1.04, or less than 1 percent, to close at $191.76 on the Nasdaq.
